Latest Regulatory Milestones News

VRX Silica Limited has successfully concluded the environmental appeal process for its Arrowsmith North Silica Sand Project, with the WA Minister for Environment confirming the adequacy of the EPA assessment. The company is now advancing financing discussions and offtake agreements as it awaits formal project approval.

PainChek Limited has raised A$7.5 million through a strongly supported placement to accelerate its US market entry following anticipated FDA clearance and expand its innovative AI pain assessment technology internationally.

Latrobe Magnesium Limited has extended its Pilot Project Licence with EPA Victoria until February 2027, paving the way to resume magnesium oxide production at its Hazelwood North site in August 2025.

Winsome Resources progresses key permitting and exploration milestones at its Adina Lithium Project while maintaining a strong cash position and deferring the Renard Option decision amid subdued lithium market conditions.

Nova Minerals supports the permit application for the West Susitna Access Road, a vital infrastructure project set to enhance mining access and economic growth in Alaska’s resource-rich region.

Imricor Medical Systems reported significant regulatory and commercial progress in Q2 CY25, including CE mark approvals and expanded clinical trials, while maintaining a strong cash position.

Piche Resources has secured key environmental approvals and completed significant groundwork at its Cerro Chacon Gold Project, while expanding its uranium tenements in Western Australia and planning further drilling at Sierra Cuadrada.

Venus Metals Corporation has secured the mining lease for its Bellchambers gold deposit, unlocking the path toward advancing development with promising drilling results and planned resource updates.

BlinkLab is advancing its FDA 510(k) clinical trials for autism and ADHD diagnostics, completing its U.S. autism pilot phase and expanding European ADHD recruitment. A recent $7.66 million capital raise supports these efforts as the company targets regulatory approvals in 2026.

Dimerix has secured a significant licensing agreement with Amicus Therapeutics for its kidney disease drug candidate DMX-200 in the US, receiving a US$30 million upfront payment and advancing its Phase 3 trial with FDA endorsement of a key clinical endpoint.

AVJennings Limited shares will halt trading following court approval of a takeover scheme by PM Nominees C Pty Ltd, marking a pivotal shift for the property developer.

Xstate Resources has pushed back the closing date of its public offer to early August, setting the stage for a potential ASX re-listing by late August following key approvals and asset acquisition.